Vaccines and Global Health: The Week in Review :: 12 June 2021

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version A pdf of the current issue is available here: 

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

G7 – COVID

Milestones :: Perspectives :: Research

 

G7 – COVID

WHO Director-General’s opening remarks at the G7 Summit – 12 June 2021
12 June 2021
Thank you, Prime Minister Johnson, and greetings to everyone. As Sir Patrick and Melinda have outlined, the pandemic is asking us many questions. We welcome and appreciate the ambition of the 100 days mission – we need bigger, faster, better for the future.

The question that every person on earth is now asking is: how and when will we end this pandemic?
We have the knowledge and tools to do it, including vaccines.

In each of your nations, public health measures in combination with vaccination is driving cases and deaths to the lowest levels since the pandemic began. But around the world, many other countries are now facing a surge in cases – and they are facing it without vaccines.

We are in the race of our lives, but it’s not a fair race, and most countries have barely left the starting line.

Our short-term targets are to vaccinate at least 10% of the population of every country by September, and at least 40% by the end of the year, as you have seen in the joint proposal by the IMF, WHO, WTO and the World Bank. To reach those targets, we need 100 million more doses right now – this month and next month – and 250 million more by September. But we must aim higher.

 

To truly end the pandemic, our goal must be to vaccinate at least 70% of the world’s population by the time you meet again in Germany next year. This can be done with the support of the G7 and G20, together. To do that, we need 11 billion doses.

We welcome the generous announcements you have made about donations of vaccines. Thank you. But we need more, and we need them faster. Immediate dose donations are vital, ideally through COVAX. But so is scaling up production, including through the use of technology transfer and intellectual property waivers.

There are many other lessons we all must learn about how to keep our nations and our world safer from future pandemics. Above all, at the root of the pandemic is a deficit of solidarity and sharing – of the data, information, resources, technology and tools that every nation needs to keep its people safe.

WHO believes the best way to close that deficit is with an international agreement – a treaty, convention, call it what you will – to provide the basis for improved preparedness, detection and response, and for improved cooperation to identify the origins of new pathogens. And I would like to join Boris in thanking Charles Michel. It would also provide a vital underpinning for a stronger WHO at the centre of the global health architecture.

With 194 Member States and 150 country offices, WHO has a unique global mandate, unique global reach and unique global legitimacy. The pandemic has shown that the world needs the World Health Organization more than ever.

We look to the G7 for your continued support for a stronger WHO, for a safer world. Thank you.

 

::::::

G7 discuss 100 Days Mission to improve readiness for future pandemics
12/06/2021
Today (12 June), G7 Leaders will discuss the 100 Days Mission, an ambitious but essential mission to have safe and effective vaccines, therapeutics and diagnostics within 100 days of a future pandemic threat being identified. The UK Government’s Chief Scientific Adviser, Sir Patrick Vallance, and Melinda French Gates will address Leaders at the Carbis Bay Summit, setting out how governments, industry, international organisations and others should work together to speed up the world’s response to future pandemic threats…
The partnership today published its report: the ‘100 Days Mission for diagnostics, therapeutics and vaccines to respond to future pandemic threats’. The report sets out recommendations for governments, industry, international organisations and others, to speed up our response to a future pandemic through research & development and best practice in business as usual and having ‘rules of the road’ to guide international responses in pandemics. The report advises that, through building on the lessons and extraordinary scientific response to COVID-19, the world should aim for the following interventions to be available, safe, effective and affordable within the first 100 days of WHO declaring a pandemic:
:: Vaccines ready to be produced at scale for global deployment;
:: An initial regimen of therapeutics; and,
:: Accurate and approved rapid point of care diagnostic tests…

G7 leaders to agree landmark global health declaration
Published 11 June 2021
:: Leaders will sign-up to Carbis Bay Declaration on health, vowing to take steps to ensure the global devastation caused by coronavirus is never repeated
:: UK will establish a new centre to develop vaccines to prevent zoonotic diseases spreading from animals to humans
:: G7 countries and guests will be joined by Sir Patrick Vallance and Melinda French Gates who will present their ‘100 day mission’ to speed up the time it takes to develop vaccines, treatments and diagnostics

G7 Health Ministers’ Meeting, communique, Oxford, 4 June, 2021
[Excerpt]
…7. We emphasise the importance of promoting and monitoring equitable global access to safe, effective, quality and affordable vaccines, therapeutics and diagnostics. We affirm support for all existing pillars of the Access to COVID-19 Tools Accelerator (ACT-A), including its COVAX facility. We are committed to addressing the financing needs in global health to support the research, development, manufacturing, and equitable distribution of safe and effective COVID-19 diagnostics, therapeutics and vaccines. We note the intention to conduct a comprehensive strategic review as a basis for a possible adaptation and extension of its mandate to the end of 2022. We commit to supporting COVAX financially, including by encouraging pledges to the facility, including at the COVAX AMC Summit, disbursing as soon as possible, providing in-kind contributions, and coordinating with and using COVAX, which is the key mechanism for global sharing of vaccines to supplement its own direct procurement, to enable the rapid equitable deployment of vaccines. In this regard, we welcome the outcome of the COVAX Advance Market Commitment Summit co-hosted by Japan and Gavi on 2 June. We emphasise our support for global sharing of safe, effective, quality and affordable vaccine doses including working with COVAX when domestic situations permit. We affirm our support for efforts to strengthen supply chains and boost and diversify global vaccine manufacturing capacity, including for the materials needed to produce vaccines, including by sharing risks, and welcome the vaccines technology transfer hub launched by WHO. We recall in this regard the Charter for Equitable Access to COVID-19 Tools and welcome the commitments made in the G7 Foreign and Development Ministers’ equitable access and collaboration statement

FACT SHEET: United States and G7+ Plan to Defeat the COVID-19 Pandemic in 2022 and Prevent the Next Pandemic

Milestones :: Perspectives :: Research

 

FACT SHEET: United States and G7+ Plan to Defeat the COVID-19 Pandemic in 2022 and Prevent the Next Pandemic
June 11, 2021 Statements and Releases [Text-bolding from original]

 

Today, President Biden welcomed the historic commitment of the leaders of the G7 and guest countries to provide more than 1 billion additional COVID-19 vaccines for the world, starting this summer, of which the United States will contribute half a billion doses.

This commitment forms the basis of a comprehensive set of G7+ actions towards ending this global pandemic in 2022. The G7+ action plan that will be agreed to by leaders in Cornwall includes vaccinating the world’s most vulnerable, providing emergency supplies, bolstering world-wide economic recovery, and positioning the international community to prepare for, prevent, detect, and respond to future biological catastrophes.

The United States will lead the G7+ in a global COVID-19 vaccination campaign, providing 500 million safe and effective COVID-19 vaccines for the world through COVAX, with delivery starting in August 2021. This donation, which President Biden announced yesterday, is the largest single donation of vaccines in history and comprises half of the G7+ commitment to provide an additional 1 billion safe and effective COVID-19 vaccine doses over the next 12 months, especially to the world’s most vulnerable.

In addition, we are taking concrete and tangible steps to meet the ambition of the G7+ and drive action to end this pandemic and prevent the next. We call on other countries and private sector partners to join us.

 

To end the global COVID-19 pandemic, the United States and the G7+ will:
:: Accelerate Vaccination of the World’s Most Vulnerable
We are fully committed to working towards the ambitious goal of ending the pandemic. Yesterday’s announcement of half a billion new vaccine doses comes on top of both the at least 80 million vaccine doses previously announced by President Biden and the $2 billion in funding which the United States has previously provided to Gavi to support COVAX. We call on countries to donate additional doses of safe and effective vaccines, strengthen vaccine readiness, and work with private sector partners to vaccinate the world.

:: Support Last Mile Vaccination and Getting Shots into Arms
The Biden-Harris Administration will be providing hundreds of millions in support for programs that provide assistance to help countries and health systems prepare for vaccination around the world, including in Latin America, Asia, and Africa. That assistance comes on top of longstanding U.S. support for countries and communities around the world for immunization and strengthening health systems.

:: Save Lives Now with PPE and Emergency Medical Supplies
The Biden-Harris Administration is investing in efforts to help fragile countries with their emergency response, including lifesaving medical and other supplies to tackle COVID-19 surges while strengthening their health systems, building capacity to manage surges, and preventing disease spread. We must expand our emergency responses, including by delivering lifesaving medical supplies, oxygen, diagnostics, therapeutics, and PPE. We are providing emergency assistance in 2021 to regions that need it most, including sending multiple flights and more than $100 million in health assistance to India, and supporting responses in South Asia and Latin America as countries experience surges in COVID-19 cases.

Through the $11.5 billion provided in the American Rescue Plan (ARP) for the global COVID-19 response, we will continue to strengthen our global response to and recovery from COVID-19, including by expanding investments in lifesaving medical supplies, including oxygen, diagnostics, therapeutics, and PPE. We urge the World Bank Group and the other Multilateral Development Banks to increase the speed of their financial support to the response.

:: Boosting Global Supply and Supporting Surge Capacity
We must increase our investments in local production capacity for safe and effective COVID-19 vaccines, therapeutics, raw materials, diagnostics, and medical supplies. We will help develop and sustain a global vaccine supply network for this pandemic and the next.

The Biden-Harris Administration is investing, through the U.S. International Development Finance Corporation (DFC), in local production capacity for safe and effective COVID-19 vaccines, which will support at least 1 billion vaccine doses by the end of 2022. This includes our efforts through the Quad Vaccine Partnership of the United States, India, Japan, and Australia, and with peer Development Finance Institutions including the IFC, Proparco, and DEG to support vaccine manufacturing in Africa – for Africa. We strongly support the aim of developing a regional network of surge capacity to produce medical countermeasures, PPE, and other lifesaving treatments and supplies.

We recognize that the above immediate actions to end the pandemic contribute to our collective longer-term preparedness. We are committed to developing sustainable surge capacity in every region to scale up medical countermeasures and supply production on a “no regrets” basis at the first sign of a health crisis.

Simultaneously, we will work expeditiously to advance global health security to prevent future biological catastrophes:
:: Transform Disease Surveillance and Early Warning
We must substantially strengthen the rapid detection of infectious disease threats. We will support the establishment of a coordinated global surveillance network to improve disease forecasting and surveillance, enable swift detection of pathogens, and translate early detection into action. We commit to accelerate development, production, and deployment of safe and effective countermeasures within 100 days.

The Biden-Harris Administration is investing $500 million from the ARP to modernize public health data and infrastructure including establishing a new Center for Epidemic Forecasting and Outbreak Analytics at the U.S. Centers for Disease Control and Prevention, which will help lead a new global pandemic early warning network. The American Jobs Plan (AJP) includes $30 billion toward building U.S. pandemic readiness, including by accelerating our ability to develop, produce, and deploy safe and effective countermeasures within 100 days.

:: Advance Global Health Security
We must work with other countries and private sector partners to reach agreement by the 2021 UN General Assembly on the creation of a catalytic global health security financing mechanism and for its sustainable funding. We also commit to establishing the needed governance, oversight, accountability and transparency for future health security threats. The Biden-Harris Administration is spearheading an effort, building a coalition of public and private partners around the world, to come to consensus and establish and sustainably fund a global health security financing mechanism in 2021. We have also requested at least $250 million through the President’s Fiscal Year 2022 Budget Request to support seed funding for this mechanism this year. We look forward to progress before this year’s United Nations General Assembly, including consensus on the governance and transparency required for future health emergencies. In this regard, the Biden-Harris Administration welcomes the Independent Panel for Pandemic Preparedness and Response (IPPPR) recommendation to establish a Global Health Threats Council at the UN.

And we will go further to Build Back Better:
:: Build Resilience to Recover
We will not stop with ending the pandemic: we must also invest in the global recovery from COVID-19. The Biden-Harris Administration strongly supports assisting countries in recovering from the pandemic’s aftershocks. We seek to reorient our development finance tools to strengthen health systems, catalyze infrastructure investment in for low-and middle-income countries and reverse the secondary impacts that have sent millions into poverty and hunger, disrupting and destabilizing education, political, economic, and social systems. We strongly support the effort to recycle Special Drawing Rights (SDRs) to further support health needs. We will also maintain our strong commitment to global education and strengthening the resiliency of food systems, including by mitigating the disproportionate disruptions experienced by women and girls.

The United States remains committed to saving lives and ending the COVID-19 pandemic now. We look forward to the adoption of the G7+ action plan this weekend. We call on other countries and private sector partners to support this ambition.

Gavi welcomes U.S. decision to procure 500 million vaccine doses to be delivered through COVAX

Milestones :: Perspectives :: Research

 

Gavi welcomes U.S. decision to procure 500 million vaccine doses to be delivered through COVAX
:: US Government scheme, announced today, will see 500 million doses of the Pfizer-BioNTech vaccine distributed through the COVAX Facility
:: Deliveries will begin in August, with 200 million to be shipped in 2021 and a further 300 million by June 2022
Geneva, 10 June 2021 – Gavi, the Vaccine Alliance, today welcomes the decision by the United States Government to procure 500 million COVID-19 vaccine doses on behalf of the COVAX Facility.
Under the plan, 200 million doses of the Pfizer-BioNTech vaccine will be delivered in 2021, starting in August, with a further 300 million shipped in the first half of 2022.
The doses will be made available to all 92 economies eligible for donor-funded vaccines via the Gavi COVAX Advance Market Commitment (AMC), as well as member states of the African Union.
The 500 million doses outlined in this plan are separate from an earlier decision by the US Government to share 80 million doses starting in June as part of a broader global vaccine sharing strategy

Biopharmaceutical industry welcomes COVID-19 vaccine-sharing pledges but warn challenges remain to urgently address vaccine inequity

Milestones :: Perspectives :: Research

 

Biopharmaceutical industry welcomes COVID-19 vaccine-sharing pledges but warn challenges remain to urgently address vaccine inequity
:: G7 country dose sharing announcements on the back of the G20 pledges combined with vaccine makers commitment to make available 3,5 billion extra doses are an important starting point towards achieving vaccine equity.
:: Innovative vaccine manufacturers and biotech companies at the forefront producing COVID-19 vaccines are confident if scarcity of raw materials and trade barriers are addressed that they will be able to produce at least 10 billion by the end of 2021, which will be enough doses to vaccinate the world’s adult population.
:: The doses pledged to LMICs need to be efficiently distributed, in appropriate quantities to assist uptake and to avoid further surges of the coronavirus pandemic.

Geneva, 11 June 2021: Recent announcements today by G7 countries and last month by G20 countries of over 1 billion doses to be made available to low- and middle-income (LMIC) countries in 2020 and 2021 is an important step towards advancing fair and equitable access to COVID-19 vaccines around the world. Thankfully, the doses are available, not least because the global biopharmaceutical industry is on track to produce at least 10 billion doses by end 2021 of which 3,5 billion doses have been made in new commitments for COVAX last month at the G20 Global Health Summit. But vaccine equity will only be achieved if the doses are distributed efficiently and with due regard to the capacity of different LMICs to roll out their immunization plans across their priority populations.

Organizations representing the innovative vaccine manufacturers and biotech companies involved in the historic scaling up of vaccines manufacturing announced on 19th May 2021 their “Five steps to urgently advance COVID-19 vaccine equity”, where they committed to working with governments, IGOs and NGOs to support stepping up dose sharing, continue efforts to optimize production, call out trade barriers to be eliminated, support country readiness, and continue driving innovation.

“This weekend’s announcements from the G7 in the UK send a welcome and very important signal to the world: that it is not acceptable to deepen inequity by ignoring that whole swathes of the world have yet to vaccinate their healthcare workers and their most vulnerable populations, while a dozen of countries have sufficient doses to be considering vaccinating school children. Enlightened self interest which recognizes that sustained dose sharing across the globe is the only way out of this global health crisis” says Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

 

To date, 2 billion doses have been pledged in Q1 2021 by innovative vaccine manufacturers and biotech companies, a further 3,5 billion doses were pledged at cost or discounted to LMICs to COVAX or other established mechanisms at the G20 (May 2021). As manufacturing output picks up momentum, industry is confident that it will make the estimated 10 billion plus dose target by the end of 2021; with over 2,2 billion doses already produced by the end of May. But reaching the World Health Organization’s targets of 10% of the world’s population vaccinated by September and 30% by the end of the year depends swift translation of the pledges into action that allows a planned efficient and sustained roll out. According to UNICEF, G7 countries could donate 20% of available vaccines to COVAX now, without any significant delay in current plans to vaccinate their adult population.

The current pledges of over 1 billion doses to COVAX are welcome, but it will be important to work closely with LMICs to ensure that they are ready and able to deploy available doses within their shelf life.

World Trade Organisation

Milestones :: Perspectives :: Research

 

World Trade Organisation

Members approach text-based discussions for an urgent IP response to COVID-19
9 June 2021
WTO members moved closer to a text-based process to address the proposals put forward by delegations aimed at improving the international response to COVID-19 and achieving the common goal of providing global equitable access to vaccines and other medical products. At the formal meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) on 8-9 June, members also addressed the continued exemption for least-developed countries (LDCs) from TRIPS obligations, currently set to expire on 1 July 2021.
[See COVID above for detail]

WTO receives updated petition calling for universally accessible and affordable COVID-19 vaccines
7 June 2021
A petition signed by over 2.7 million people from around the world calling for universal access to affordable COVID-19 vaccines was received by the WTO on 7 June. It was delivered by Avaaz, an online activist network, and the People’s Vaccine Alliance, a coalition of organizations. The petition brings together the work of more than 40 organizations worldwide, including the Online Progressive Engagement Network (OPEN), Public Citizen, Frontline AIDS, Amnesty International, Oxfam, SumOfUs and the European Citizens’ Initiative for No Profit on Pandemic.

To G7 leaders, pharmaceutical companies CEOs, and all member countries of the World Trade Organization:
We call on you urgently to ensure access to lifesaving Covid-19 vaccines, treatments and equipment for everyone in the world. Patents should be suspended, technological knowledge shared freely and openly, and no profiteering allowed during this pandemic. Governments, scientists and pharmaceutical companies must cooperate and combine resources to ensure no one is left behind. The pandemic will not be over, until it’s over everywhere.

COVID-19 response: freely available ISO standards

Milestones :: Perspectives :: Research

 

COVID – Standards

COVID-19 response: freely available ISO standards
International Organization for Standardization
2 June 2021
The list below has been compiled to support global efforts in dealing with the COVID-19 crisis. They are freely available in read-only format:
ISO 374-5:2016, Protective gloves against dangerous chemicals and micro-organisms – Part 5: Terminology and performance requirements for micro-organisms risk
ISO 5356-1:2015, Anaesthetic and respiratory equipment — Conical connectors — Part 1: Cones and sockets
ISO 10651-4:2002, Lung ventilators — Part 4: Particular requirements for operator-powered resuscitators
ISO 10651-5:2006, Lung ventilators for medical use — Particular requirements for basic safety and essential performance — Part 5: Gas-powered emergency resuscitators
ISO 10993-1:2018, Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process
ISO 13485:2016, Medical devices — Quality management systems – Requirements for regulatory purposes
ISO 13688:2013, Protective clothing – General requirements
ISO 13688:2013/AMD 1:2021, Protective clothing — General requirements — AMENDMENT 1
ISO/TS 16976-8:2013, Respiratory protective devices — Human factors — Part 8: Ergonomic factors
ISO 17510:2015, Medical devices — Sleep apnoea breathing therapy — Masks and application accessories
ISO 18082:2014, Anaesthetic and respiratory equipment — Dimensions of non-interchangeable screw-threaded (NIST) low-pressure connectors for medical gases [Including ISO 18082:2014/AMD 1:2017, AMENDMENT 1]
ISO 18562-1:2017, Biocompatibility evaluation of breathing gas pathways in healthcare applications — Part 1: Evaluation and testing within a risk management process
ISO 18562-2:2017, Biocompatibility evaluation of breathing gas pathways in healthcare applications — Part 2: Tests for emissions of particulate matter
ISO 18562-3:2017, Biocompatibility evaluation of breathing gas pathways in healthcare applications — Part 3: Tests for emissions of volatile organic compounds (VOCs)
ISO 18562-4:2017, Biocompatibility evaluation of breathing gas pathways in healthcare applications — Part 4: Tests for leachables in condensate
ISO 19223:2019, Lung ventilators and related equipment — Vocabulary and semantics
ISO 20395:2019, Biotechnology — Requirements for evaluating the performance of quantification methods for nucleic acid target sequences — qPCR and dPCR
ISO 22301:2019, Security and resilience – Business continuity management systems –Requirements
ISO 22316:2017, Security and resilience – Organizational resilience – Principles and attributes
ISO 22320:2018, Security and resilience – Emergency management – Guidelines for incident management
ISO 22395:2018, Security and resilience – Community resilience – Guidelines for supporting vulnerable persons in an emergency
ISO 22609:2004, Clothing for protection against infectious agents — Medical face masks — Test method for resistance against penetration by synthetic blood (fixed volume, horizontally projected)
ISO 31000:2018, Risk management – Guidelines
ISO/PAS 45005:2020, Occupational health and safety management — General guidelines for safe working during the COVID-19 pandemic
ISO 80601-2-12:2020, Medical electrical equipment — Part 2-12: Particular requirements for basic safety and essential performance of critical care ventilators
ISO 80601-2-13:2011, Medical electrical equipment — Part 2-13: Particular requirements for basic safety and essential performance of an anaesthetic workstation [Including: ISO 80601-2-13:2011/Amd.1:2015, AMENDMENT 1 and ISO 80601-2-13:2011/Amd.2:2018, AMENDMENT 2]
ISO 80601-2-70:2020, Medical electrical equipment — Part 2-70: Particular requirements for basic safety and essential performance of sleep apnoea breathing therapy equipment
ISO 80601-2-74:2017, Medical electrical equipment — Part 2-74: Particular requirements for basic safety and essential performance of respiratory humidifying equipment
ISO 80601-2-79:2018, Medical electrical equipment — Part 2-79: Particular requirements for basic safety and essential performance of ventilatory support equipment for ventilatory impairment
ISO 80601-2-80:2018, Medical electrical equipment — Part 2-80: Particular requirements for basic safety and essential performance of ventilatory support equipment for ventilatory insufficiency
ISO 80601-2-84:2020, Medical electrical equipment — Part 2-84: Particular requirements for the basic safety and essential performance of ventilators for the emergency medical services environment
This action has been coordinated with the International Electrotechnical Commission (IEC), who are making complementary standards freely available at go.iec.ch/covid19faq.

COVID-19 Data Explorer: Global Humanitarian Operations

Milestones :: Perspectives :: Research

 

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
Jun 12, 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA
Global COVID-19 Figures: 174M total confirmed cases; 3.8M total confirmed deaths
Global vaccines administered: 2.33B
Number of Countries: 26 [26]
COVAX First Allocations (Number of Doses): 73M [73M]
COVAX Delivered (Number of Doses): 15M [15M]
Other Delivered (Number of Doses): 33M [33M]
Total Delivered (Number of Doses): 49M [49M]
Total Administered (Number of Doses): 36M [36M]

Coronavirus [COVID-19] – WHO Public Health Emergency of International Concern (PHEIC)

Milestones :: Perspectives :: Research

 

Coronavirus [COVID-19] – WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

 

Weekly Epidemiological and Operational updates
Last update: 12 Jun 2021
Confirmed cases :: 174 918 667 [week ago: 172 242 495]
Confirmed deaths :: 3 782 490 [week ago 3 709 397]
Vaccine doses administered: 2 156 550 767 [week ago: 1 638 006 899]

 

::::::

Weekly epidemiological update on COVID-19 – 8 June 2021
Overview
Global case and death incidences continued to decrease with over 3 million new cases and over 73 000 new deaths reported in the past week, a 15% and an 8% decrease respectively as compared to the week before. In the past week, the European and South-East Asia Regions reported marked declines in the number of new cases while the African Region reported an increase as compared to the previous week.
In this edition, a special focus update is provided on SARS-CoV-2 Variants of Interest (VOIs) and Variants of Concern (VOCs) Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2). This includes updates on emerging evidence surrounding the phenotypic characteristics of VOCs (transmissibility, disease severity, risk of reinfection, and impacts on diagnostics and vaccine performance), as well as updates on the geographic distribution of VOCs.

[Excerpt, p. 5]

Weekly operational update on COVID-19 – 7 June 2021
Overview
In this edition of the COVID-19 Weekly Operational Update, highlights of country-level actions and WHO support to countries include:
:: Second training of trainers on infection prevention and control (IPC) in Mauritius
:: COVAX ships an additional 559 200 doses of COVID-19 vaccines to Malaysia
:: The Hospital of Tomorrow: WHO/Europe supports Tuscany Region in Italy in hospital redesign
:: Support for COVID-19 response amidst staggering health needs in the occupied Palestinian territory, including east Jerusalem
:: Strengthening vaccine rollout preparedness for refugees in Cox’s Bazar
:: The launch of the SPRP 2021 Monitoring and Evaluation Framework and progress on a subset of indicators
:: Librarians supporting the timely dissemination of COVID-19 seroprevalence data through GOARN and a workshop on health systems for health security
:: Updates on WHO’s financing to support countries in SPRP 2021 implementation and provision of critical supplies.

::::::
::::::

Draft landscape and tracker of COVID-19 candidate vaccines
11 June 2021
The COVID-19 candidate vaccine landscape and tracker database compiles detailed information on COVID-19 vaccine candidates in development.
The landscape is updated regularly – twice a week (Tuesday and Friday, 17:00 CET).
Download: https://cdn.who.int/media/docs/default-source/blue-print/28.05.2021-novel-coronavirus_landscape_covid-19.xlsx.zip?sfvrsn=e352acfa_3&download=true

::::::

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 28 May 2021
For 19 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date
[click on the link above for full scale view]
03 June 2021 [Not updated]

COVID Vaccine Developer/Manufacturer Announcements [organizations from WHO EUL/PQ listing above]

Milestones :: Perspectives :: Research

 

COVID Vaccine Developer/Manufacturer Announcements [organizations from WHO EUL/PQ listing above]

 

AstraZeneca
Press Releases – No new digest announcements identified

Bharat Biotech, India
Press Releases – Website not responding at inquiry [third week]

BioCubaFarma – Cuba
Últimas Noticias
Se aprueba primer ensayo clínico en Cuba para población pediátrica.
Resumen:  El Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED) aprueba el primer ensayo clínico a ejecutarse en el país en población pediátrica con el candidato vacunal Soberana contra la Covid 19, desarrollado por el Instituto Finlay de Vacunas (IFV).
04/06/2021 16:15:31    |   BioCubaFarma
[Google translate: The first clinical trial in Cuba for the pediatric population is approved…CECMED) approves the first clinical trial to be carried out in the country in a pediatric population with the Sovereign vaccine candidate against Covid 19, developed by the Finlay Vaccine Institute (IFV).]

 

CanSinoBIO
News – No new digest announcements identified

Clover Biopharmaceuticals – China
News – No new digest announcements identified

 

Curevac [Bayer Ag – Germany]
News – No new digest announcements identified

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements identified

 

Janssen/JNJ
Press Releases
Jun 11, 2021 United States
Johnson & Johnson Statement on Supply of its Single-shot COVID-19 Vaccine
Johnson & Johnson confirms the United States Food & Drug Administration (FDA) has authorized two batches of drug substance, manufactured at the Emergent BioSolutions, Inc. Bayview facility, under the Emergency Use Authorization (EUA) for its single-shot COVID-19 vaccine.
“Since establishing our COVID-19 vaccine program, Johnson & Johnson has committed to producing safe, high-quality vaccines in order to bring health and hope to people everywhere,” said Kathy Wengel, Executive Vice President and Chief Global Supply Chain Officer, Johnson & Johnson. “Today’s decisions represent progress in our continued efforts to make a difference in this pandemic on a global scale, and we appreciate the close collaboration with the FDA and global health authorities.”
The Company continues to substantially expand its global vaccine manufacturing network as we work with regulatory and health authorities to supply our COVID-19 vaccine worldwide…

Jun 10, 2021 United States
Johnson & Johnson statement on FDA approval of shelf life extension for company’s COVID-19 vaccine
We are pleased to confirm the U.S. Food & Drug Administration (FDA) has authorized an extension of the shelf life for the Johnson & Johnson single-shot COVID-19 vaccine from 3 months to 4.5 months. The decision is based on data from ongoing stability assessment studies, which have demonstrated that the vaccine is stable at 4.5 months when refrigerated at temperatures of 36 – 46 degrees Fahrenheit (2 – 8 degrees Celsius)…

 

Moderna
Press Releases
June 11, 2021
Moderna and Tabuk Pharmaceuticals Partner to Commercialize Moderna’s COVID-19 Vaccine in Saudi Arabia

June 10, 2021
Moderna Files for Emergency Use Authorization for its COVID-19 Vaccine in Adolescents in the United States

June 7, 2021
Moderna and Medison Pharma Partner to Commercialize Moderna’s COVID-19 Vaccine Across Central Eastern Europe and Israel

June 7, 2021
Moderna Files for Authorization with Health Canada for its COVID-19 Vaccine in Adolescents

June 7, 2021
Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union

 

Novavax
Press Releases
Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
6/11/2021
– New vaccine based on the recombinant spike protein antigen (rS-B.1.351) from Beta (B.1.351) virus lineage highly immunogenic in mice and produced neutralizing antibodies
– Primates boosted with rS-B.1.351 vaccine induced strong neutralizing immune response to original SARS-CoV-2, Alpha (B.1.1.7) and Beta (B.1.351) variant strains
– Humans immunized with original NVX-CoV2373 vaccine demonstrated robust antibody responses to original SARS-CoV-2 strain, as well as to the Alpha (B.1.1.7) and Beta (B.1.351) variant strains
– Data available ahead of publication via preprint server, bioRxiv

 

Pfizer
Recent Press Releases
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
Thursday, June 10, 2021
:: U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022
:: Doses to be donated to approximately 100 low- and lower middle-income countries including those in the African Union via the COVAX Facility
:: Effort is part of the companies’ recent pledge of two billion doses to ensure global equitable access to the vaccine

U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older
Tuesday, June 08, 2021 – 07:12pm
:: First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia,1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and deaths in the U.S.
:: Helps protect against more serotypes of pneumococcal disease than any other conjugate vaccine
:: Builds on Pfizer’s more than 20-year legacy and innovation in developing pneumococcal conjugate vaccines

 

Serum Institute of India
NEWS & ANNOUNCEMENTS – No corporate announcements identified
[Last media release April 21, 2021]

 

Sinopharm/WIBPBIBP
News – No new digest announcements identified

 

Sinovac
Press Releases – No new digest announcements identified

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

 

::::::

GSK
Press releases for media – No new digest announcements identified

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Vaccines and Related Biological Products Advisory Committee
:: Vaccines and Related Biological Products Advisory Committee June 10, 2021 Meeting Announcement
:: Meeting Information
:: Event Materials

 

::::::

White House [U.S.]
Briefing Room – Selected Major COVID Announcements
FACT SHEET: United States and G7+ Plan to Defeat the COVID-19 Pandemic in 2022 and Prevent the Next Pandemic
June 11, 2021 • Statements and Releases
[See COVID above for detail]

Remarks by President Biden on the COVID-19 Vaccination Program and the Effort to Defeat COVID-19 Globally
June 10, 2021 • Speeches and Remarks

Background Press Call by Senior Administration Officials on the President’s Historic COVID-19 Vaccine Announcement
June 10, 2021 • Press Briefings

FACT SHEET: President Biden Announces Historic Vaccine Donation: Half a Billion Pfizer Vaccines to the World’s Lowest-Income Nations
June 10, 2021 • Statements and Releases

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

European Medicines Agency
News & Press Releases
News: COVID-19 Vaccine Janssen: authorities in EU take steps to safeguard vaccine quality (new)
Last updated: 11/06/2021

News: Additional manufacturing capacity for Moderna’s COVID-19 vaccine (new)
CHMP, Last updated: 11/06/2021

 

News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 June 2021 (new)
PRAC, Last updated: 11/06/2021
PRAC concludes review of signal of capillary leak syndrome with COVID-19 vaccine Vaxzevria
EMA’s safety committee (PRAC) has concluded that people who have previously had capillary leak syndrome must not be vaccinated with Vaxzevria (formerly COVID-19 Vaccine AstraZeneca). The committee also concluded that capillary leak syndrome should be added to the product information as a new side effect of the vaccine, together with a warning to raise awareness among healthcare professionals and patients of this risk…

 

News: COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis (new)
PRAC, Last updated: 11/06/2021

 

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
Latest Updates
Publication
Rapid risk assessment: Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 15th update
Risk assessment – 10 Jun 2021
Although SARS-CoV-2 transmission remains widespread in large parts of the EU/EEA, most countries report declining trends in 14-day COVID-19 notification rates, hospital and intensive care unit (ICU) occupancy, and mortality. Many countries have initiated partial lifting of different non-pharmaceutical interventions (NPIs) that aim to reduce the degree of citizens physical contact and mobility. Since January 2021, EU/EEA countries have reported an increase in the number and proportion of SARS-CoV-2 cases of variants of concern (VOC) associated with increasing transmissibility and/or severity, with Alpha (B.1.1.7) the current dominant variant across the EU/EEA. Estimates across the region show that a large proportion of the population across Europe still remains susceptible to SARS-CoV-2 and that population immunity is far from being reached. As of 3 June, the median cumulative vaccine uptake in the EU/EEA adult population (aged 18 years and older) had reached 46.2% for at least one vaccine dose and 22.3% for the full vaccination course. The highest level of vaccine uptake was observed among the elderly aged over 80, in which the uptake reached 80.5% for at least one dose and 66.3% for full vaccination coverage. For healthcare workers, the median level of at least one dose uptake was 87% and the median uptake for the full vaccination course was 65.2%. Increased vaccine supply has allowed countries to expand eligibility for vaccination to younger age groups.

 

European Commission
https://ec.europa.eu/commission/presscorner/home/en
No new relevant announcements identified.

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

Russia: Sputnik V – “the first registered COVID-19 vaccine”
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
Single-dose Sputnik Light vaccine registered in Mongolia
Press release, 11.06.2021

Sputnik V demonstrates high 94.3% efficacy and high safety profile during the vaccination campaign in Bahrain
Press release, 09.06.2021

Single-dose Sputnik Light vaccine approved for use in the Republic of the Congo
Press release, 07.06.2021

Brazil becomes the 67th country in the world to authorize Sputnik V vaccine
Press release, 05.06.2021

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Milestones :: Perspectives :: Research

 

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

 

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

08.06.2021
Revised Guidelines for implementation of National COVID Vaccination Program

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
No new digest content identified.

POLIO Public Health Emergency of International Concern (PHEIC)

Emergencies

POLIO
Public Health Emergency of International Concern (PHEIC)

Polio this week as of 09 June 2021
:: Today, the Global Polio Eradication Initiative (GPEI) launched the Polio Eradication Strategy 2022-2026: Delivering on a Promise at a virtual event, to overcome the remaining challenges to ending polio, including setbacks caused by COVID-19. Read the press release here.
:: “We need to continue supporting the Global Polio Eradication Initiative, whose surveillance capacity and ability to reach vulnerable communities are critical in many countries to prevent and respond to pandemics.” – health ministers of the G7 countries. Read more…..

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):
:: Afghanistan: one cVDPV2 case
:: Pakistan: two WPV1 and one cVDPV2 positive environmental samples
:: Burkina Faso: one cVDPV2 case

 

::::::
::::::

GPEI Strategy 2022-2026

Polio Eradication Strategy 2022-2026: Delivering on a Promise
Pre-publication version, as of 10 June 2021
Published by the World Health Organization (WHO) on behalf of the Global Polio Eradication Initiative (GPEI).
EXECUTIVE SUMMARY [excerpt]
Over the last decade, the Global Polio Eradication Initiative (GPEI) made steady progress on the path to eradication. Wild poliovirus types 2 and 3 (WPV2 and WPV3) were declared eradicated in 2015 and 2019, respectively; the World Health Organization (WHO) South-East Asia Region was declared free of poliovirus in 2014; and most recently, the WHO African Region was certified free of wild poliovirus (WPV) in August 2020. However, the final steps towards eradication have proven the most difficult.

The GPEI now faces programmatic and epidemiological challenges that demand new approaches to place the partnership and impacted countries on emergency footing (see Annex A). To achieve a polio-free world, the GPEI has re-envisioned the endgame pathway with an urgent call for collective ownership and accountability across the GPEI partnership and with governments, communities and all other stakeholders.

The Polio Eradication Strategy 2022–2026 offers a comprehensive set of actions that will position the GPEI to deliver on a promise that brought the world together in a collective commitment to eradicate polio. These actions, many of which are already underway in 2021, will strengthen and empower the GPEI to meet challenges head-on and achieve and sustain a polio-free world.

The GPEI will transform its approach in each region and country through five mutually reinforcing objectives that lay the foundation to achieve two elemental goals:
Goal One to permanently interrupt poliovirus transmission in the final WPV-endemic countries of Afghanistan and Pakistan, and
Goal Two to stop circulating vaccine-derived poliovirus (cVDPV) transmission and prevent outbreaks in non-endemic countries…

 

THE GPEI POLIO OVERSIGHT BOARD
Chris Elias
President, Global Development Division, Bill & Melinda Gates Foundation
2021 Chair of the Polio Oversight Board
Seth Berkley
Chief Executive Officer, Gavi, the Vaccine Alliance
Henrietta Fore
UNICEF Executive Director
Mike McGovern
Chair, International PolioPlus Committee, Rotary International
Tedros Adhanom Ghebreyesus
WHO Director-General
Rochelle Walensky
Director, US Centers for Disease Control and Prevention

::::::

Countries reaffirm commitment to ending polio at launch of new eradication strategy
10 June 2021 News release
Today, the Global Polio Eradication Initiative (GPEI) will launch the Polio Eradication Strategy 2022-2026: Delivering on a Promise at a virtual event, to overcome the remaining challenges to ending polio, including setbacks caused by COVID-19. While polio cases have fallen 99.9% since 1988, polio remains a Public Health Emergency of International Concern (PHEIC) and persistent barriers to reaching every child with polio vaccines and the pandemic have contributed to an increase in polio cases. Last year, 1226 cases of all forms of polio were recorded compared to 138 in 2018.  

In 2020, the GPEI paused polio door-to-door campaigns for four months to protect communities from the spread of COVID-19 and contributed up to 30,000 programme staff and over $100 million in polio resources to support pandemic response in almost 50 countries.

Leaders from the two countries yet to interrupt wild polio transmission—Pakistan and Afghanistan—called for renewed global solidarity and the continued resources necessary to eradicate this vaccine-preventable disease. They committed to strengthening their partnership with GPEI to improve vaccination campaigns and engagement with communities at high risk of polio.

The 2022-2026 Strategy underscores the urgency of getting eradication efforts back on track and offers a comprehensive set of actions that will position the GPEI to achieve a polio-free world. These actions, many of which are underway in 2021, include:

:: further integrating polio activities with essential health services—including routine immunization—and building closer partnerships with high-risk communities to co-design immunization events and better meet their health needs, particularly in Pakistan and Afghanistan;

:: applying a gender equality lens to the implementation of programme activities, recognizing the importance of female workers to build community trust and improve vaccine acceptance;

:: strengthening advocacy to urge greater accountability and ownership of the program at all levels, including enhanced performance measurement and engagement with new partners, such as the new Eastern Mediterranean Regional Subcommittee on Polio Eradication and Outbreaks; and,

:: implementing innovative new tools, such as digital payments to frontline health workers, to further improve the impact and efficiency of polio campaigns.

“With this new Strategy, the GPEI has clearly outlined how to overcome the final barriers to securing a polio-free world and improve the health and wellbeing of communities for generations to come,” said Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization and member of the Polio Oversight Board. “But to succeed, we urgently need renewed political and financial commitments from governments and donors. Polio eradication is at a pivotal moment. It is important we capitalise on the momentum of the new Strategy and make history together by ending this disease.”…

::::::
::::::

WHO/OCHA Emergencies

Editor’s Note:
WHO has apparently reorganized and fundamentally shifted how it judges and tracks “emergencies”. We found no announcement of descriptive information to share and present the webpage structure as encountered below.

Health emergencies list – WHO
The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences.

Ebola outbreak, Democratic Republic of the Congo, 2021

Ebola outbreak outbreak, N’Zerekore, Guinea, 2021

Coronavirus disease (COVID-19) pandemic

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020

Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020

Ebola outbreak, Democratic Republic of the Congo, 2018

Yemen crisis

Syria crisis

Somalia crisis

Nigeria crisis

Ebola outbreak, Democratic Republic of the Congo, 2017

Zika virus disease outbreak, 2015-2016

Ebola outbreak: West Africa, 2014-2016

Iraq crisis

South Sudan crisis

Avian influenza A (H7N9) virus outbreak

Middle East respiratory syndrome (MERS-CoV) outbreak

Influenza A (H1N1) virus, 2009-2010 pandemic

::::::

UN OCHA – Current Emergencies
Current Corporate Emergencies
Ethiopia
Ethiopia Humanitarian Bulletin Issue #7 10 May – 6 June 2021
HIGHLIGHTS
:: Partners are implementing CERF-funded anticipatory action projects to mitigate the impact of drought and prevent a food security crisis.
:: The Federal and Regional Governments are preparing to implement a phased return/relocation plan for conflict-displaced people (IDPs) in various parts of the country ahead of the Kiremt/summer rainy season.

::::::
::::::

WHO & Regional Offices [to 12 Jun 2021]

WHO & Regional Offices [to 12 Jun 2021]
https://www.who.int/
11 June 2021 Statement
Statement for healthcare professionals: How COVID-19 vaccines are regulated for safety and effectiveness

11 June 2021 Departmental news
Approaches to sustained control of neglected tropical diseases need to evolve and adapt

11 June 2021 Departmental news
26 International experts to kickstart the One Health High Level Expert Panel (OHHLEP)

11 June 2021 Departmental news
New HIV/AIDS political declaration seeks to end inequalities and get on track to end AIDS by 2030

10 June 2021 News release
New WHO guidance seeks to put an end to human rights violations in mental health care

10 June 2021 News release
Countries reaffirm commitment to ending polio at launch of new eradication strategy

9 June 2021 Departmental news
Global Leaders from Health and Energy pave the way for a Clean and Healthy Future for All

9 June 2021 Statement
Council on the Economics of Health For All issues brief on equitable health innovation

9 June 2021 Departmental news
Record response to WHO’s call for antimicrobial resistance surveillance reports in 2020

8 June 2021 Departmental news
WHO publishes new guidance to accelerate in-country registration of WHO prequalified in vitro diagnostics

8 June 2021 Departmental news
New Policy Action Paper highlights feasible policy interventions for addressing the under representation of women in global health and care leadership

7 June 2021 Departmental news
WHO guideline development group meeting on WHO antenatal care guidelines: Update on early ultrasound scan recommendation

 

::::::

Weekly Epidemiological Record, Vol. 96, No. 23, pp. 217–228 11 June 2021
:: Considerations for pneumococcal vaccination in older adults

 

::::::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: How Senegal prepared for COVID-19 surge 11 June 2021
As the second wave of COVID-19 infections surged in early 2021, Senegal stepped up measures to cope with the anticipated rise in the number of patients needing critical care. Professor Daye Ka, Infectious and Tropical Disease Expert and member of Senegal’s COVID-19 task force, explains the steps taken to avert hospitals being overrun by a drastic rise in critically ill patients.
:: Tackling surges in severe COVID-19 cases in Africa 11 June 2021
Africa has the highest global mortality rate among critically ill COVID-19 patients despite having the world’s lowest COVID-19 infections and deaths overall, a recent study published by the Lancet found. Shortage of critical care resources and their underuse are some of the contributing factors. Dr Christian Owoo, a Senior Lecturer in the Department of Anaesthesia, University of Ghana Medical School and a Consultant Anaesthetist/Intensivist and Head of Intensive Care Unit at Korle Bu Teaching Hospital in Accra, discusses ways to prevent severe COVID-19 illness and avert a surge in deaths.
:: The system stalling COVID-19 importation into Rwanda 11 June 2021
The aircraft engines power down as disembarking passengers rummage through their carry-on bags for documents in readiness for immigration. This is Kigali International Airport, a busy regional hub. The country has implemented an innovative electronic tracking system to stop the domestic spread of COVID-19 from arriving passengers.

WHO Region of the Americas PAHO
No new digest content identified

WHO South-East Asia Region SEARO
:: 8 June 2021 News release
WHO tri-regional policy dialogue seeks solutions to challenges facing international mobility of health professionals

WHO European Region EURO
:: With the pandemic far from over, we all need to practice #SummerSense 10-06-2021
:: COVID-19: Learning from experience 10-06-2021
:: WHO tri-regional policy dialogue seeks solutions for international mobility of health professionals 09-06-2021
:: WHO study points to interventions for improving cardiovascular health in Tajikistan 09-06-2021
:: WHO/Europe and EuroHealthNet sign agreement to collaborate on addressing health inequalities and promoting sustainable development 09-06-2021

WHO Eastern Mediterranean Region EMRO
:: Update on COVID-19 in WHO’s Eastern Mediterranean Region
9 June 2021 – As of 08 June 2021 (11:59 PM), the Eastern Mediterranean Region has reported 10 353 336 confirmed COVID-19 cases and 206 573 deaths. While the total number of cases has declined over the past 6 weeks and the number of deaths stabilized, 9 countries reported an increase in cases last week, compared to the previous week. These include Somalia,…

WHO Western Pacific Region
No new digest content identified

CDC/ACIP [U.S.] [to 12 Jun 2021]

CDC/ACIP [U.S.] [to 12 Jun 2021]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases, Announcements
CDC COVID-19 Study Shows mRNA Vaccines Reduce Risk of Infection by 91 Percent for Fully Vaccinated People
June 7, 2021
A new CDC study finds the mRNA COVID-19 vaccines authorized by the Food and Drug Administration (Pfizer-BioNTech and Moderna) reduce the risk of infection by 91 percent for fully vaccinated people. This adds to the growing body of real-world evidence of their effectiveness. Importantly, this study also is among the first to show that mRNA vaccination benefits people who get COVID-19 despite being fully vaccinated (14 or more days after dose 2) or partially vaccinated (14 or more days after dose 1 to 13 days after dose 2).7, 2021

MMWR News Synopsis Friday, June 10, 2021

MMWR News Synopsis Friday, June 10, 2021
:: Progress Toward Rubella Elimination — World Health Organization European Region, 2005–2019
:: Impact of the COVID-19 Pandemic on Administration of Selected Routine Childhood and Adolescent Vaccinations — 10 U.S. Jurisdictions, March–September 2020
:: Genomic Surveillance for SARS-CoV-2 Variants Circulating in the United States, December 2020–May 2021
:: Hospitalization of Adolescents Aged 12–17 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 1, 2020–April 24, 2021 (Early Release June 4, 2021)
:: Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine — United States, September 6, 2020–May 1, 2021 (Early Release June 8, 2021)

Impact of the COVID-19 Pandemic on Administration of Selected Routine Childhood and Adolescent Vaccinations — 10 U.S. Jurisdictions, March–September 2020
Analysis of immunization data from 10 U.S. jurisdictions shows a substantial decrease in routine vaccinations during March–May 2020, when many jurisdictions enacted stay-at-home orders due to the COVID-19 pandemic, compared with the same period during in 2018 and 2019. To prevent outbreaks of vaccine-preventable diseases, public health practitioners and health care providers should promote routine vaccination among children to ensure they are fully vaccinated as schools reopen for in-person learning.
Since the COVID-19 pandemic started, early reports from some state and local jurisdictions suggested that routine pediatric vaccinations had sharply declined, placing U.S. children at risk for vaccine-preventable diseases. To further understand the impact of the pandemic on routine childhood and adolescent vaccination, vaccine administration data from March through September 2020 from 10 U.S. jurisdictions were assessed. Fewer doses of routine childhood and adolescent vaccines were recorded during March–September 2020 than during the same periods in 2018 and 2019 in all 10 jurisdictions. The number of vaccine doses administered declined during March–May 2020, when many jurisdictions enacted stay-at-home orders. The number of vaccine doses administered during June–September, after many jurisdictions lifted stay-at-home orders in summer 2020, approached pre-pandemic levels. However, there was not a substantial increase above pre-pandemic levels, which would have been necessary to catch up children who did not receive routine vaccinations on time. This lag in catch-up vaccination might pose a serious public health threat, resulting in vaccine-preventable disease outbreaks, especially as schools reopen for in-person learning. Health care providers should assess the immunization status of all pediatric patients, including adolescents, and contact those who are behind schedule to ensure that all children are up to date.

China CDC

China CDC
http://www.chinacdc.cn/en/
CCDC Weekly – Weekly Reports: Current Volume (3)
2021-06-11 / No. 24
PDF of this issue
No new digest content identified.

National Health Commission of the People’s Republic of China [to 12 Jun 2021]
http://en.nhc.gov.cn/
News
June 11: Daily briefing on novel coronavirus cases in China
On June 10, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 22 new cases of confirmed infections.

At least 70 pct of China’s target population to be vaccinated by year end: Official
2021-06-08

21 COVID-19 vaccines enter clinical trials in China
2021-06-08
BEIJING — China has witnessed 21 COVID-19 vaccines enter clinical trials, an official with the National Health Commission (NHC) said on June 6.
far, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, according to Zeng Yixin, deputy head of the NHC.
A total of eight COVID-19 vaccines have been approved for phase III clinical trial overseas, and one messenger RNA (mRNA) COVID-19 vaccine met the ethical requirements for phase III clinical trial overseas, Zeng said.

National Medical Products Administration – PRC [to 12 Jun 2021]
http://english.nmpa.gov.cn/news.html
News
China reaches 800-million-dose milestone in vaccination campaign
2021-06-10
The National Health Commission said it took 25 days to reach 200 million doses from 100 million; 16 days to 300 million and only six days to 600 million from 500 million, showing increased injection efficiency.

Organization Announcements

Organization Announcements
Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

 

Paul G. Allen Frontiers Group [to 12 Jun 2021]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
News
No new digest content identified.

 

BARDA – U.S. Department of HHS [to 12 Jun 2021]
https://www.phe.gov/about/barda/Pages/default.aspx
News
June 8, 2021: Biden Administration Recommends Policy Changes to Secure U.S. Pharmaceutical Supply Chain

 

BMGF – Gates Foundation [to 12 Jun 2021]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

 

Bill & Melinda Gates Medical Research Institute [to 12 Jun 2021]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
Jun 10, 2021
Penny Heaton @drpennyheaton
It’s a bittersweet day as I announce my departure from @GatesMRI to join @JanssenGlobal. I’m grateful for the opportunity to have led such an incredible organization – and I’m excited to lead a team transforming global #vaccine development.

 

CARB-X [to 12 Jun 2021]
https://carb-x.org/
News
06.08.2021  |
CARB-X is funding Accelerate Diagnostics to develop a rapid optical imaging diagnostic for sepsis and serious antibiotic-resistant bacterial infections
CARB-X is awarding Accelerate Diagnostics, a Tucson, Arizona, USA, biotech company, up to US$578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. Accelerate would be eligible for up to $2.1 million in additional funds from CARB-X if the project meets certain milestones, subject to available funds.

 

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 12 Jun 2021]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions and posting of all segments of Vaccines and Global Health: The Week in Review are available here.
:: [NEW] Informed Consent: A Monthly Review – June 2021 is now posted here

 

CEPI – Coalition for Epidemic Preparedness Innovations [to 12 Jun 2021]
http://cepi.net/
Latest News
G7 summit: an opportunity to conquer the pandemic
As leaders of the world’s wealthiest economies convene in Cornwall, UK, we have a once in a generation moment to build a world better placed to deal with the next pandemic.
COVID-19
11 Jun 2021

Vaccine specialists and global health experts selected for CEPI’s Scientific Advisory Committee
The group will provide key guidance and recommendations on CEPI’s vaccine R&D programmes and broader outbreak response efforts.
COVID-19
09 Jun 2021

Conquering COVID-19 and future pandemic threats
Richard Hatchett, CEO of CEPI, discuss how to control COVID-19 and what needs to be done to end pandemics.
COVID-19
07 Jun 2021

 

DARPA – Defense Advanced Research Projects Agency [to 12 Jun 2021
https://www.darpa.mil/news
News
No new digest content identified.

 

Duke Global Health Innovation Center [to 12 Jun 2021]

Home


WEEKLY COVID VACCINE RESEARCH UPDATE
Last dated update: FRIDAY, June 4, 2021

 

EDCTP [to 12 Jun 2021]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

 

Emory Vaccine Center [to 12 Jun 2021]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

 

European Vaccine Initiative [to 12 Jun 2021]
http://www.euvaccine.eu/
Latest News
No new digest content identified.

 

FDA [to 12 Jun 2021]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements /Selected Details
June 11, 2021 – Coronavirus (COVID-19) Update: June 11, 2021

June 11, 2021 – FDA Takes Steps to Increase Availability of COVID-19 Vaccine
Following careful review and deliberation, the U.S. Food and Drug Administration is taking important steps that will allow a critically needed supply of the Janssen (Johnson & Johnson) COVID-19 Vaccine to be made available.
The agency is announcing today that it is authorizing for use, under the emergency use authorization (EUA) for the Janssen COVID-19 vaccine, two batches of vaccine drug substance manufactured at the Emergent BioSolutions facility in Baltimore. Before making this decision, the FDA conducted a thorough review of facility records and the results of quality testing performed by the manufacturer. Based on this review and considering the current COVID-19 public health emergency, the FDA concluded these batches are suitable for use. While the FDA is not yet ready to include the Emergent BioSolutions plant in the Janssen EUA as an authorized manufacturing facility, the agency continues to work through issues there with Janssen and Emergent BioSolutions management…

June 8, 2021 – Coronavirus (COVID-19) Update: June 8, 2021

 

Fondation Merieux [to 12 Jun 2021]
http://www.fondation-merieux.org/
News, Events
No new digest content identified

 

Gavi [to 12 Jun 2021]
https://www.gavi.org/
News Releases
10 June 2021
Gavi welcomes U.S. decision to procure 500 million vaccine doses to be delivered through COVAX
[See COVID above for full text]

 

GHIT Fund [to 12 Jun 2021]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 212 with the aim of developing new tools to tackle infectious diseases that
No new digest content identified.

 

Global Fund [to 12 Jun 2021]
https://www.theglobalfund.org/en/news/
News & Stories
No new digest content identified

 

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 12 Jun 2021]
https://www.glopid-r.org/news/
News
Global COVID-19 research agenda still missing the priorities of low- and middle-income countries
07/05/2021
An article published today in The Lancet calls for urgent collaboration and coordination for unmet, underfunded COVID-19 research priorities in low-resource settings.   Over…

 

Hilleman Laboratories [to 12 Jun 2021]
http://www.hillemanlabs.org/
Website not responding at inquiry

 

Human Vaccines Project [to 12 Jun 2021]
http://www.humanvaccinesproject.org/
No new digest content identified.

 

IAVI [to 12 Jun 2021]
https://www.iavi.org/newsroom
PRESS RELEASES/FEATURES
No new digest content identified.

 

 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

 

ICRC [to 12 Jun 2021]
https://www.icrc.org/en/whats-new
Selected News Releases, Statements, Reports
Global Advisory Board on digital threats during conflict
A high-level advisory board is supporting the ICRC on legal and policy challenges to protect civilians from cyber threats and other digital risks during conflict
09-06-2021 | Article

 

 

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

 

 

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

 

IFRC [to 12 Jun 2021]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
Asia Pacific, Myanmar
Myanmar: Red Cross ramps up response as humanitarian crisis deepens
Kuala Lumpur/Yangon/Geneva, 8 June 2021 – The Myanmar Red Cross supported by the International Federation of Red Cross and Red Crescent Societies (IFRC) is scaling up emergency support as hundreds of thousands of people in Myanmar need immediate assist …
8 June 2021

Austria, France, Germany, Italy, Spain, Turkey
Red Cross Red Crescent warns of the devastating impacts of the COVID-19 pandemic on children and young people in Europe
Several studies by Red Cross and Red Crescent societies across Europe show an alarming pattern, which requires increased efforts to tackle inequity and assist those most in need.
7 June 2021

 

Institut Pasteur [to 12 Jun 2021]
https://www.pasteur.fr/en/press-area
Press Info
No new digest content identified.

 

IOM / International Organization for Migration [to 12 Jun 2021]
http://www.iom.int/press-room/press-releases
News
Empowering Migrants is Key to COVID-19 Recovery
2021-06-10 19:38
A joint research by the International Organization for Migration (IOM) and the United Nations Development Programme (UNDP) conducted in nine countries shows that the pandemic has increased poverty and unemployment for many migrants and their families. Data collected in Bangladesh, Belarus, El Salvador, Guinea, Indonesia, Kyrgyz Republic, Lesotho, the Republic of Moldova and Peru showed that travel restrictions have left a significant number of migrants stranded, with others forced to return to their home countries where they face hardship…
The study further shows that:
:: As many as 180,000 Indonesian migrant workers returned home in 2020, with 75 percent facing unemployment and some households seeing a 60 percent drop in income.
:: More than 150,000 of the Kyrgyz Republic’s 1 million migrants returned from working abroad in a context marked by the already-high unemployment and 10 percent contraction in the economy brought about by COVID-19, placing pressure on public services.
:: Increased discrimination and stigma among women in Kyrgyz Republic with 80 percent restricted from managing their own money by their families.
::In La Unión in El Salvador, where much of the population works overseas and has since returned, one in three households had a family member who lost their job…

 

IRC International Rescue Committee [to 12 Jun 2021]
http://www.rescue.org/press-release-index
Media highlights [Selected]
No new digest content identified.

 

IVAC [to 12 Jun 2021]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
Webinar: Vaccines, Primary Care, and Public Health—After COVID, What’s Next?
When: Wednesday, July 7, 2021 from 12:00pm to 1:00pm ET
Join Dr. Tom Frieden, President and CEO of Resolve to Save Lives, for a 60-minute webinar hosted by the International Vaccine Access Center to discuss what roles and strategies vaccines, primary care and public health will play while we prepare for life after COVID-19.

 

IVI [to 12 Jun 2021]
http://www.ivi.int/
Selected IVI News, Announcements, Events
No new digest content identified.

 

JEE Alliance [to 12 Jun 2021]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

 

Johns Hopkins Center for Health Security [to 12 Jun 2021]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
No new digest content identified.

 

MSF/Médecins Sans Frontières [to 12 Jun 2021]
http://www.msf.org/
Latest [Selected Announcements
No new digest content identified.

 

National Academy of Medicine – USA [to 12 Jun 2021]
https://nam.edu/programs/
Selected News/Programs
No new digest content identified.

 

National Vaccine Program Office – U.S. HHS [to 12 Jun 2021]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
NVAC 2021 Meetings
June 16-17, 2021 NVAC Meeting = Agenda

 

NIH [to 12 Jun 2021]
http://www.nih.gov/news-events/news-releases
News Releases
NIH leaders detail commitment to end structural racism in biomedical science
June 10, 2021 — Scientists, administrators, and staff set forth a frame work to end structural racism across the biomedical research enterprise

 

UN OCHA Office for the Coordination of Humanitarian Affairs [to 12 Jun 2021]
https://www.unocha.org/
Press Releases
No new digest content identified.

 

PATH [to 12 Jun 2021]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

 

Rockefeller Foundation [to 12 Jun 2021]
https://www.rockefellerfoundation.org/
Reports/Press Releases
Jun 10 2021
Press Releases
More than 8 in 10 Parents Plan to Send Their Children to In-person School in the Fall
New research, conducted by RAND Corporation and commissioned by The Rockefeller Foundation, details parents’ preferences for in-person school safety measures and how they differ on racial and ethnic lines. New York …

Jun 09 2021
Press Releases
The Rockefeller Foundation Announces Key Grants & Collaborations to Strengthen Global Genomic Sequencing & Data Sharing
The Rockefeller Foundation announces over $20 million in funding and several non-financial collaborations to help strengthen global capabilities to detect and respond to pandemic threats by strengthening organizations’ abilities to sequence and share genomic information and other data rapidly. Collaborating with over 20 organizations from the public, private, and non-profit sectors, this enhanced network will begin to shape The Rockefeller Foundation’s pandemic prevention institute.

 

Sabin Vaccine Institute [to 12 Jun 2021]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

 

UNAIDS [to 12 Jun 2021]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
11 June 2021
What responses to HIV and COVID-19 in Asia and the Pacific led by civil society can teach us

11 June 2021
City leaders unite to regain momentum in the urban HIV response

11 June 2021
Young key populations from Asia and the Pacific claiming their space at the 2021 High-Level Meeting on AIDS

11 June 2021
First Lady of Côte d’Ivoire sponsors national consultation on paediatric HIV and tuberculosis

10 June 2021
Putting people and communities at the centre of the HIV response

10 June 2021
Resources and funding for an effective AIDS response

10 June 2021
Addressing inequalities to end AIDS: 10 years to 2030

9 June 2021
Prioritizing human rights to end inequalities and end AIDS

8 June 2021
Opening remarks by UNAIDS Executive Director Winnie Byanyima at the High-Level Meeting on AIDS

8 June 2021
Strengthening national social protection systems

8 June 2021
Science, HIV and COVID-19—where are we headed?

8 June 2021
Caribbean stakeholders call for focus on key populations and community-led approaches to HIV and COVID-19

7 June 2021
Faith2EndAIDS, Faith2EndInequality

7 June 2021
Costa Rica joins Global Partnership for Action to Eliminate all Forms of HIV-Related Stigma and Discrimination

7 June 2021
Jamaica partnership works to promote human rights

 

UNDP United Nations Development Programme [to 12 Jun 2021]
https://www.undp.org/news-centre
News Centre
No new digest content identified.

 

UNHCR Office of the United Nations High Commissioner for Refugees [to 12 Jun 2021]
http://www.unhcr.org/en-us/media-centre.htmlS
Selected News Releases, Announcements
Global legal community steps up for refugees amid pandemic, providing 165,000 hours of free legal aid
8 Jun 2021

 

UNICEF [to 12 Jun 2021]
https://www.unicef.org/media/press-releases
Selected Press Releases, Statements
Statement
06/08/2021
UNICEF statement on UK budget cuts
NEW YORK, 8 June 2021 – “We remain deeply concerned by the decision of the UK Government to reduce funding to UNICEF. We depend on these resources to sustain our humanitarian and development programmes for millions of children around the world, helping us to reach them before, during and after crises.
“Any cuts to these vital funds will have serious consequences for the most vulnerable children, especially now that the COVID-19 pandemic has led to a global spike in the number of those in need of essential education, protection, health and water services. We estimate that 150 million additional children are living in multidimensional poverty because of the pandemic.
“It is too soon to know the full impact that UK funding cuts will have on UNICEF programmes, but early indications paint an alarming picture.
“The UK Government has already announced a 60 per cent reduction in core funding to UNICEF, funding which enables us to react swiftly to emergencies and help children recover afterwards…

Remarks
06/08/2021
UNICEF Executive Director Henrietta Fore’s remarks at the Humanitarian Liaison Working Group on Equitable Access to COVID-19 Vaccines in Humanitarian Settings
As prepared for delivery
… “Third — we need funding.
“Yes, delivering vaccines within emergencies is more expensive. And yes, donors have already spent billions to establish the COVAX Facility.
“But they won’t see a return on this investment until every person is vaccinated — including in fragile settings.
“Without effective delivery systems, vaccines are little more than vials on a shelf. Despite the higher cost involved, we urgently need more funding to get these vaccines delivered and into people’s arms.
“The establishment of the Humanitarian Buffer was an important milestone. But as a humanitarian community, we need to turn up the volume on the need for vaccine-delivery funding across all emergencies.
“And fourth — we need to ensure that we maintain, and continue to fund, routine vaccinations and other essential health interventions in humanitarian emergencies.
The onset of the pandemic last year devastated these efforts, disrupting planned immunization campaigns across 83 countries. While 35 countries have since resumed these campaigns, 48 countries have not — leaving millions of children vulnerable to preventable disease.
“We urge that the COVID-19 vaccines being delivered — especially those in humanitarian settings including through the Humanitarian Buffer — are delivered alongside a full package of health services, including routine immunizations for other diseases…

Press release
06/07/2021
UNICEF Goodwill Ambassadors join 28* high-profile UNICEF supporters to urge G7 countries to donate COVID-19 vaccine doses to poor countries
Ahead of G7 leaders summit this weekend, UNICEF Ambassadors and Supporters publish joint letter urging G7 leaders to commit to sharing at least 20 per cent of available COVID-19 vaccine doses.

 

Unitaid [to 12 Jun 2021]
https://unitaid.org/
Featured News
UK government funding cuts: statement from Unitaid’s Chair and Executive Director
Geneva, 10 June 2021 – Unitaid has been informed by the Government of the United Kingdom that our funding from the UK has been cut from an expected £77 million in 2021 to just £6 million. This includes a deferred contribution of £33 million from 2020.
While recognising that the pandemic has placed governments in an unexpected and challenging economic situation, we deeply regret such a significant step back from a strong partner and the second largest donor to the organisation, at a moment when equitable access to health solutions is more needed than ever.
Beyond the direct devastating effects of COVID-19, these fifteen months of pandemic have already set back the progress made so far in the fight against HIV/AIDS, malaria, and tuberculosis by ten to twelve years.
Investments are urgently needed, not only to boost manufacturing capacity, supply and the equitable distribution of tools against the COVID-19 pandemic, but also crucially to mitigate against collateral damage in the global fight against diseases which predominantly impact the most vulnerable.
The announced cuts will reduce the resources available to Unitaid to provide end-to-end game-changing solutions that address the multiple challenges facing global health. However, it is important to stress that in spite of this context, the organisation remains strongly committed to its mandate.
We hope the decrease in the UK contribution is only temporary.

 

Vaccination Acceptance & Demand Initiative [Sabin) [to 12 Jun 2021]
https://www.vaccineacceptance.org/
Announcements
No new digest content identified.

 

Vaccine Confidence Project [to 12 Jun 2021]
http://www.vaccineconfidence.org/
News, Research and Reports
Coronavirus global impact
Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

 

Vaccine Education Center – Children’s Hospital of Philadelphia [to 12 Jun 2021]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

 

Wellcome Trust [to 12 Jun 2021]
https://wellcome.ac.uk/news
News and reports
Opinion
Author – Sophie Evekink
3 things G7 leaders can do to end the Covid-19 pandemic
7 June 2021

Opinion
Author – Will Hall
The road to 1 billion vaccines – what Covid-19 dose sharing commitments are needed from the G7
6 June 2021
As the G7 leaders meet in Cornwall this month, we are calling on them to share 1 billion vaccine doses before the end of 2021, starting immediately.

 

The Wistar Institute [to 12 Jun 2021]
https://www.wistar.org/news/press-releases
Press Releases
No new digest content identified.

 

WFPHA: World Federation of Public Health Associations [to 12 Jun 2021]
https://www.wfpha.org/
Latest News
No new digest content identified.

 

World Bank [to 12 Jun 2021]
http://www.worldbank.org/en/news/all
Selected News, Announcements
World Bank Group President David Malpass: Statement on COVID-19 Response and Vaccinations for Developing Countries
WASHINGTON, June 11, 2021—World Bank Group President David Malpass today issued the following statement in advance of the G7 Leaders’ Summit: “I warmly welcome the G7’s vital work on helping to accelerate…
Date: June 11, 2021 Type: Statement
[See COVID above for detail]

13 million People to Receive COVID-19 vaccination in Ghana
WASHINGTON, June 10, 2021 –The World Bank today approved a $200 million Ghana COVID-19 Emergency Preparedness and Response Project Second Additional Financing. In collaboration with the COVAX Facility…
Date: June 10, 2021 Type: Press Release

World Bank’s Operational Response to COVID-19 (Coronavirus) in East Asia and the Pacific
The COVID-19 (coronavirus) pandemic has taken a drastic human toll, and the economic and social impacts of the pandemic are reverberating globally. As countries around the world work to contain the spread…
Date: June 10, 2021 Type: Brief

Additional COVID-19 Funding to Help Lao PDR Reach 50% Vaccination Target
Vientiane, June 10, 2021 – An additional US$15 million has been made available to help the Lao PDR stop the spread of the COVID-19 pandemic in the country, following an agreement between the World Bank…
Date: June 10, 2021 Type: Press Release

Sierra Leone Receives Additional Support for Access and Effective Vaccines Deployment
WASHINGTON, June 8, 2021 — The World Bank approved an $8.5 million grant in additional financing to support affordable and equitable access to COVID-19 vaccines in Sierra Leone. The funds will provide…
Date: June 08, 2021 Type: Press Release

Global Recovery Strong but Uneven as Many Developing Countries Struggle with the Pandemic’s Lasting Effects
Output to remain below pre-COVID trends despite robust rebound by US and ChinaWASHINGTON, June 8, 2021 — The global economy is expected to expand 5.6% in 2021, the fastest post-recession pace in 80 years…
Date: June 08, 2021 Type: Press Release L

Georgia’s Vaccination Rollout to be Strengthened with $34.5 Million Additional Financing from World Bank
WASHINGTON, June 7, 2021 – Georgia’s COVID-19 vaccination efforts will gain a major boost thanks to $34.5 million in additional financing approved today by the World Bank. This financing augments the original…
Date: June 07, 2021 Type: Press Release

 

World Customs Organization – WCO [to 12 Jun 2021]
http://www.wcoomd.org/
Latest News – Selected Items
09 June 2021
WCO supports global fight against illicit trafficking during a joint Press Conference in Antwerp

 

World Organisation for Animal Health (OIE) [to 12 Jun 2021]
https://www.oie.int/en/for-the-media/press-releases/2021/
Press Releases
Dr Monique Éloit is re-elected as Director General of the World Organisation for Animal Health (OIE)
During her second term (June 2021-June 2026), Dr Éloit will provide leadership over the implementation of the 7th Strategic Plan, focused on global animal health governance.
Paris, 3 June 2021 – At the close of the 88th General Session of the World Assembly, OIE national Delegates confirmed Dr Monique Éloit for a second term as OIE Director General. The vote was held by secret ballot and followed the “one country, one vote” rule. Dr Éloit has served as the Director General since 2016. Over the past five years, she has strived to restructure the actions of the Organisation to modernise its different programmes and to enhance the transparency of internal procedures, with the aim to consolidate OIE’s position among major international organisations.
While thanking the Assembly for her re-election, she reasserted her conviction that “the OIE should not remain solely focused on traditional animal health topics, such as livestock disease control, but that it should go beyond them, by investing more significantly in veterinary public health subjects as they have an impact on the whole of society.”…

::::::

 

ARM [Alliance for Regenerative Medicine] [to 12 Jun 2021]
Press Releases – Alliance for Regenerative Medicine (alliancerm.org)
Selected Press Releases
No new digest content identified.

 

BIO [to 12 Jun 2021]
https://www.bio.org/press-releases
Press Releases
BIO Takes on Health Equity in Clinical Trials
June 10, 2021
First-ever BIO Clinical Trial Diversity Summit will engage stakeholders to build a sustainable and equitable clinical development ecosystem

 

DCVMN – Developing Country Vaccine Manufacturers Network [to 12 Jun 2021]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

 

ICBA – International Council of Biotechnology Associations [to 12 Jun 2021]
https://internationalbiotech.org/news/
News
No new digest content identified.

 

IFPMA [to 12 Jun 2021]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
Biopharmaceutical industry welcomes COVID-19 vaccine-sharing pledges but warn challenges remain to urgently address vaccine inequity
11 June 2021
[See COVID above for detail]

R&D bio-pharmaceutical groups warn about rise in COVID-19 falsified medical products in Africa and call
10 June 2021
The COVID-19 pandemic has led to a global surge in reported falsified medical products including personal protective equipment, diagnostic tests, and more recently falsified or substandard medicines, “cures” and vaccines.  In Africa, the challenge of falsified and substandard medicines is even more pronounced with over 40% of all the counterfeits reported to the WHO, emanating from Africa. In November last year, a large consignment of counterfeit Covid vaccines was seized in South Africa.
Association of Representatives of Ethical Pharmaceutical Industries (AREPI), The Innovative Pharmaceutical association South Africa (IPASA), Kenya Association of Pharmaceutical Industry (KAPI) and the Association des Industriels Pharmaceutiques en Afrique Francophone Subsaharienne (LIPA), together with International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) call on the African and global health communities to raise awareness about the dangers of substandard and falsified medical products during this particularly challenging time for Global Health…

Global pharmaceutical industry response to G7 communiqués on antimicrobial resistance
08 June 2021

 

PhRMA [to 12 Jun 2021]
http://www.phrma.org/
Latest News
Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics
June 9, 2021
Research is focused on finding ways to help improve or correct brain function in serious brain health disorders, and to help it stay that way.
Blog Post

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Transgenerational Trauma

AMA Journal of Ethics
Volume 23, Number 6: E435-504 June 2021
https://journalofethics.ama-assn.org/issue/transgenerational-trauma

 

Transgenerational Trauma
One thing that makes trauma transgenerational is narrative. Narrative, for example, is what makes a Confederate flag from 1865 flint for insurrection in 2021. Consequences of global and domestic insults, such as slavery and forced migration, have long ramified intergenerationally in communities, families, and individuals’ bodies. Legacies of trauma travel in stories across places and over time, and their effects include health status inequity and cumulative stress embodiment. Transmission of historically entrenched patterns of oppression also influence persons’ lived experiences of marginalization, convey health risk, and can play out during clinical encounters.

Inequities in childhood immunisation coverage associated with socioeconomic, geographic, maternal, child, and place of birth characteristics in Kenya

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 12 Jun 2021)

 

Inequities in childhood immunisation coverage associated with socioeconomic, geographic, maternal, child, and place of birth characteristics in Kenya
The global Immunisation Agenda 2030 highlights coverage and equity as a strategic priority goal to reach high equitable immunisation coverage at national levels and in all districts. We estimated inequities in…
Authors: Simon Allan, Ifedayo M. O. Adetifa and Kaja Abbas
Citation: BMC Infectious Diseases 2021 21:553
Content type: Research
Published on: 11 June 2021

A policy Delphi study to validate the key implications of data sharing (KIDS) framework for pediatric genomics in Canada

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 12 Jun 2021)

 

A policy Delphi study to validate the key implications of data sharing (KIDS) framework for pediatric genomics in Canada
he highly sensitive nature of genomic and associated clinical data, coupled with the consent-related vulnerabilities of children together accentuate ethical, legal and social issues (ELSI) concerning data sharing. The Key Implications of Data Sharing (KIDS) framework was therefore developed to address a need for institutional guidance on genomic data governance but has yet to be validated among data sharing practitioners in practice settings. This study qualitatively explored areas of consensus and dissensus of the KIDS Framework from the perspectives of Canadian clinician-scientists, genomic researchers, IRB members, and pediatric ethicists.
Authors: Vasiliki Rahimzadeh, Gillian Bartlett and Bartha Maria Knoppers
Content type: Research article
9 June 2021

A phase IV, multi-centre, randomized clinical trial comparing two pertussis-containing vaccines in pregnant women in England and vaccine responses in their infants

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 12 Jun 2021)

 

A phase IV, multi-centre, randomized clinical trial comparing two pertussis-containing vaccines in pregnant women in England and vaccine responses in their infants
Pertussis vaccines containing three or five pertussis antigens are recommended in pregnancy in many countries, but no studies have compared the effect on infants’ antigen-specific immunoglobulin G (IgG) concen…
Authors: Christine Elizabeth Jones, Anna Calvert, Jo Southern, Mary Matheson, Nick Andrews, Asma Khalil, Hannah Cuthbertson, Bassam Hallis, Anna England, Paul T. Heath and Elizabeth Miller
Citation: BMC Medicine 2021 19:138
Content type: Research article
Published on: 8 June 2021

A survey on COVID-19 vaccine acceptance and concern among Malaysians

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 12 Jun 2021)

 

A survey on COVID-19 vaccine acceptance and concern among Malaysians
Vaccination is an effective way to curtail the burden of COVID-19 in which success depends on a high acceptance of the vaccine. However, addressing concerns among vaccine-hesitant individuals is essential to a…
Authors: S. A. R. Syed Alwi, E. Rafidah, A. Zurraini, O. Juslina, I. B. Brohi and S. Lukas
Citation: BMC Public Health 2021 21:1129
Content type: Research
Published on: 12 June 2021

Sociodemographic factors associated with acceptance of COVID-19 vaccine and clinical trials in Uganda: a cross-sectional study in western Uganda

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 12 Jun 2021)

 

Sociodemographic factors associated with acceptance of COVID-19 vaccine and clinical trials in Uganda: a cross-sectional study in western Uganda
Health experts agree that widespread use of safe and effective vaccines will rapidly contain the COVID-19 pandemic. The big question is whether these vaccines can easily be accepted by their end-users. Our stu…
Authors: Isaac Echoru, Patricia Decanar Ajambo, Emmanuel Keirania and Edmund E. M. Bukenya
Citation: BMC Public Health 2021 21:1106
Content type: Research article
Published on: 10 June 2021

Vaccination coverage estimates and utilization patterns of inactivated enterovirus 71 vaccine post vaccine introduction in Ningbo, China

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 12 Jun 2021)

 

Vaccination coverage estimates and utilization patterns of inactivated enterovirus 71 vaccine post vaccine introduction in Ningbo, China
In China, enterovirus 71 (EV71) is the major etiological agents of hand foot mouth disease that poses severe risks to children’s health. Since 2015, three inactivated EV71 vaccines have been approved for use. …
Authors: Lixia Ye, Jieping Chen, Ting Fang, Rui Ma, Jianmei Wang, Xingqiang Pan, Hongjun Dong and Guozhang Xu
Citation: BMC Public Health 2021 21:1118
Content type: Research article
Published on: 10 June 2021

Willingness to receive future COVID-19 vaccines following the COVID-19 epidemic in Shanghai, China

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 12 Jun 2021)

 

Willingness to receive future COVID-19 vaccines following the COVID-19 epidemic in Shanghai, China
There are no pharmacological interventions currently available to prevent the transmission of SARS-CoV-2 or to treat COVID-19. The development of vaccines against COVID-19 is essential to contain the pandemic….
Authors: Yehong Zhou, Junjie Zhang, Wenwen Wu, Man Liang and Qiang-Song Wu
Citation: BMC Public Health 2021 21:1103
Content type: Research
Published on: 9 June 2021

Affirming NIH’s commitment to addressing structural racism in the biomedical research enterprise

Cell
Jun 10, 2021 Volume 184 Issue 12 p3075-3348
https://www.cell.com/cell/current

 

Commentary
Affirming NIH’s commitment to addressing structural racism in the biomedical research enterprise
Francis S. Collins, et al. NIH UNITE
Open Access
NIH has acknowledged and committed to ending structural racism. The framework for NIH’s approach, summarized here, includes understanding barriers; developing robust health disparities/equity research; improving its internal culture; being transparent and accountable; and changing the extramural ecosystem so that diversity, equity, and inclusion are reflected in funded research and the biomedical workforce.

Tackling COVID-19 with neutralizing monoclonal antibodies

Cell
Jun 10, 2021 Volume 184 Issue 12 p3075-3348
https://www.cell.com/cell/current

 

Review
Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, David Veesler
Intense efforts have been made to develop or identify drugs to treat people with COVID-19. Monoclonal antibodies are one of the few types of drugs that have shown efficacy in the clinic.

The COVID-19 pandemic: agile versus blundering communication during a worldwide crisis: Important lessons for efficient communication to maintain public trust and ensure public safety

EMBO Reports
Volume 22 Issue 6 4 June 2021
https://www.embopress.org/toc/14693178/current

 

Science & Society 25 May 2021 Open Access
The COVID-19 pandemic: agile versus blundering communication during a worldwide crisis: Important lessons for efficient communication to maintain public trust and ensure public safety
Gaby-Fleur Böl
Governments’ measures to control the COVID-19 pandemic and public reaction hold important lessons for science and risk communication in times of crisis.

Building resource constraints and feasibility considerations in mathematical models for infectious disease: A systematic literature review

Epidemics
Volume 35 June 2021
https://www.sciencedirect.com/journal/epidemics/vol/35/suppl/C

 

Research article Open access
Building resource constraints and feasibility considerations in mathematical models for infectious disease: A systematic literature review
Fiammetta M. Bozzani, Anna Vassall, Gabriela B. Gomez
Article 100450

Assessing the nationwide impact of COVID-19 mitigation policies on the transmission rate of SARS-CoV-2 in Brazil

Epidemics
Volume 35 June 2021
https://www.sciencedirect.com/journal/epidemics/vol/35/suppl/C

 

Research article Open access
Assessing the nationwide impact of COVID-19 mitigation policies on the transmission rate of SARS-CoV-2 in Brazil
Daniel C.P. Jorge, Moreno S. Rodrigues, Mateus S. Silva, Luciana L. Cardim, … Juliane F. Oliveira
Article 100465

The impact of surveillance and other factors on detection of emergent and circulating vaccine derived polioviruses

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 12 Jun 2021]

 

Research Article metrics AWAITING PEER REVIEW
The impact of surveillance and other factors on detection of emergent and circulating vaccine derived polioviruses [version 1; peer review: awaiting peer review]
Megan Auzenbergs, Holly Fountain, Grace Macklin, Hil Lyons, Kathleen M O’Reilly
Peer Reviewers Invited
Funder: Bill and Melinda Gates Foundation
PUBLISHED 11 Jun 2021

Appraising and addressing design and implementation failure in global health: A pragmatic framework

Global Public Health
Volume 16, Issue 7 (2021)
http://www.tandfonline.com/toc/rgph20/current

 

Article commentary
Appraising and addressing design and implementation failure in global health: A pragmatic framework
Ejemai Amaize Eboreime, John Olajide Olawepo, Aduragbemi Banke-Thomas, Ibukun-Oluwa Omolade Abejirinde & Seye Abimbola
Pages: 1122-1130
Published online: 08 Sep 2020

The constitutional economics of the World Health Organization

Health Economics, Policy and Law 
Volume 16 – Issue 3 – July 2021
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue

 

Article
The constitutional economics of the World Health Organization
Eric C. Ip
Published online by Cambridge University Press: 03 August 2020, pp. 325-339
This paper brings a constitutional economics perspective to bear on the World Health Organization (WHO), the flagship United Nations intergovernmental health organisation, which is obligated by its Constitution to achieve ‘the highest possible level of health’ for the world’s peoples…

The effects of polio eradication efforts on health systems: a cross-country analysis using the Develop–Distort Dilemma

Health Policy and Planning
Volume 36, Issue 5, June 2021
https://academic.oup.com/heapol/issue/36/5

 

ORIGINAL ARTICLES
The effects of polio eradication efforts on health systems: a cross-country analysis using the Develop–Distort Dilemma
Daniela C Rodriguez, Abigail H Neel, Yodi Mahendradhata, Wakgari Deressa, Eme Owoaje
Health Policy and Planning, Volume 36, Issue 5, June 2021, Pages 707–719, https://doi.org/10.1093/heapol/czab044

Localisation and local humanitarian action

Humanitarian Exchange Magazine
Number 79, May 2021
https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/

 

Localisation and local humanitarian action
by HPN October 2020
The theme of this edition of Humanitarian Exchange is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies,  non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported.  Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Association of Maternal Influenza Vaccination During Pregnancy With Early Childhood Health Outcomes

JAMA
June 8, 2021, Vol 325, No. 22, Pages 2235-2322
https://jamanetwork.com/journals/jama/currentissue

 

Original Investigation
Association of Maternal Influenza Vaccination During Pregnancy With Early Childhood Health Outcomes
Azar Mehrabadi, PhD; Linda Dodds, PhD; Noni E. MacDonald, MD, MS; et al.
JAMA. 2021;325(22):2285-2293. doi:10.1001/jama.2021.6778
This population-based cohort study uses a birth registry linked with health administrative data to assess the association between maternal influenza vaccination during pregnancy and early childhood health outcomes in Nova Scotia, Canada.

Overview of the Issue

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 32, Number 2, May 2021 Supplement
https://muse.jhu.edu/issue/44396

 

Table of Contents
Overview of the Issue
Kevin B. Johnson, Tiffani J. Bright, Cheryl R. Clark
…The importance of techquity—defined as the strategic development and deployment of technology in health care and health to advance health equity—was even more apparent after the events of 2020. COVID-19 upended access to care and illuminated the impact of structural racism as a cause for a widening gap of access during the pandemic. Black Lives Matter became more than a trending hashtag on Twitter, or a movement resulting in peaceful protests and calls for policy reform: it put additional focus on the issue of race as a social and not a biological construct and called into question the rationale for common practices in health care that were triggered by race. A notable example was the emerging realization that kidney function assessment was tied to race and hardwired into many of our electronic health records. The real-world evidence around our lack of techquity was incontrovertible.
This Supplemental Issue of JHCPU provides articles that describe challenges to techquity, frameworks to improve the role of technology in care, and examples of how technology can transform health, public health, and health care…